<DOC>
	<DOCNO>NCT00131755</DOCNO>
	<brief_summary>The purpose study find Diazoxide partly retain insulin production newly diagnose type 1 diabetes patient .</brief_summary>
	<brief_title>Efficacy Diazoxide Type 1 Diabetes</brief_title>
	<detailed_description>At time diagnosis subject type 1 diabetes retain significant endogenous insulin secretion assess C-peptide measurement . Although sufficient need individual , residual insulin secretion important metabolic control , avoidance hypoglycemic episode , perhaps , protection diabetic complication . To retain residual endogenous insulin secretion type 1 diabetes thus highly desirable . Residual insulin secretion deteriorate course type 1 diabetes . The underlie autoimmune process major determinant deterioration . However , also measure directly target immune system could beneficial . The DCCT study randomise subject type 1 diabetes either intensive conventional insulin treatment . The intensive insulin treatment markedly retard deterioration C-peptide level 5 year observation . The favourable effect could due less hyperglycemia per se . Alternatively , effect intensive insulin treatment could secondary less degree over-stimulation patient ' beta-cells . It establish relief over-stimulation diazoxide favourably affect beta-cell function treatment retard decline residual insulin secretion subject newly diagnose type 1 diabetes . Diazoxide use clinical practice &gt; three decade without major safety concern . Disturbing , albeit reversible , side effect halt long-term study diazoxide type 1 diabetes . The researcher find low intermittent ( i.e . night time ) dose diazoxide produce measurable side effect subject type 2 diabetes . This double blind placebo control study , 35 participant newly diagnose type 1 diabetes randomise either placebo Diazoxide 6 month . The patient follow intervention least 12 month . Beta cell function glycemic control monitor .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Diazoxide</mesh_term>
	<criteria>Type 1 diabetes longer three month Positive antibody GAD IA2 Age 1840 year Cpeptide &gt; 0.2 nmol/l Drug alcohol abuse Severe concomitant disease Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>beta cell rest</keyword>
	<keyword>diazoxide</keyword>
	<keyword>insulin secretion</keyword>
</DOC>